384 related articles for article (PubMed ID: 33918705)
1. Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.
Patel CM; Wadas TJ; Shiozawa Y
Molecules; 2021 Apr; 26(8):. PubMed ID: 33918705
[TBL] [Abstract][Full Text] [Related]
2. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.
Cheetham PJ; Petrylak DP
Oncology (Williston Park); 2012 Apr; 26(4):330-7, 341. PubMed ID: 22655525
[TBL] [Abstract][Full Text] [Related]
3. Radionuclide therapy for osseous metastases in prostate cancer.
Abi-Ghanem AS; McGrath MA; Jacene HA
Semin Nucl Med; 2015 Jan; 45(1):66-80. PubMed ID: 25475380
[TBL] [Abstract][Full Text] [Related]
4. Alpha and Beta Radiation for Theragnostics.
Song H; Sgouros G
PET Clin; 2024 Jul; 19(3):307-323. PubMed ID: 38688775
[TBL] [Abstract][Full Text] [Related]
5. Radiation-based approaches for therapy and palliation of advanced prostate cancer.
Lewis B; Sartor O
Curr Opin Urol; 2012 May; 22(3):183-9. PubMed ID: 22453334
[TBL] [Abstract][Full Text] [Related]
6. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?
Bruland ØS; Nilsson S; Fisher DR; Larsen RH
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6250s-6257s. PubMed ID: 17062709
[TBL] [Abstract][Full Text] [Related]
7. [Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts].
Bertolaso P; Leroy L; Gross-Goupil M; Aupee O; Ravaud A; Roubaud G; Cazeau AL; Le Moulec S
Bull Cancer; 2017 Sep; 104(9):762-770. PubMed ID: 28797482
[TBL] [Abstract][Full Text] [Related]
8. Advances in targeted alpha therapy for prostate cancer.
De Vincentis G; Gerritsen W; Gschwend JE; Hacker M; Lewington V; O'Sullivan JM; Oya M; Pacilio M; Parker C; Shore N; Sartor O;
Ann Oncol; 2019 Nov; 30(11):1728-1739. PubMed ID: 31418764
[TBL] [Abstract][Full Text] [Related]
9. Radium-223 dichloride for the treatment of metastatic prostate cancer.
Turner PG; O'Sullivan J
Expert Opin Pharmacother; 2014 Oct; 15(14):2105-11. PubMed ID: 25186336
[TBL] [Abstract][Full Text] [Related]
10. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
Blacksburg SR; Witten MR; Haas JA
Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
[TBL] [Abstract][Full Text] [Related]
11. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
Ryan CJ; Saylor PJ; Everly JJ; Sartor O
Oncologist; 2014 Oct; 19(10):1012-8. PubMed ID: 25232039
[TBL] [Abstract][Full Text] [Related]
12. Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.
; Parker C; Lewington V; Shore N; Kratochwil C; Levy M; Lindén O; Noordzij W; Park J; Saad F
JAMA Oncol; 2018 Dec; 4(12):1765-1772. PubMed ID: 30326033
[TBL] [Abstract][Full Text] [Related]
13. Targeted α Therapies for the Treatment of Bone Metastases.
Zustovich F; Barsanti R
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29283383
[TBL] [Abstract][Full Text] [Related]
14. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.
Terrisse S; Karamouza E; Parker CC; Sartor AO; James ND; Pirrie S; Collette L; Tombal BF; Chahoud J; Smeland S; Erikstein B; Pignon JP; Fizazi K; Le Teuff G;
JAMA Oncol; 2020 Feb; 6(2):206-216. PubMed ID: 31830233
[TBL] [Abstract][Full Text] [Related]
15. Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases.
Goyal J; Antonarakis ES
Cancer Lett; 2012 Oct; 323(2):135-46. PubMed ID: 22521546
[TBL] [Abstract][Full Text] [Related]
16. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.
Pacilio M; Ventroni G; De Vincentis G; Cassano B; Pellegrini R; Di Castro E; Frantellizzi V; Follacchio GA; Garkavaya T; Lorenzon L; Ialongo P; Pani R; Mango L
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887
[TBL] [Abstract][Full Text] [Related]
17. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.
Dorff TB; Agarwal N
Asian J Androl; 2018; 20(3):215-220. PubMed ID: 29553053
[TBL] [Abstract][Full Text] [Related]
18. Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer.
Liepe K
Curr Opin Investig Drugs; 2009 Dec; 10(12):1346-58. PubMed ID: 19943206
[TBL] [Abstract][Full Text] [Related]
19. Systemic Radiotherapy of Bone Metastases With Radionuclides.
Murray I; Du Y
Clin Oncol (R Coll Radiol); 2021 Feb; 33(2):98-105. PubMed ID: 33353771
[TBL] [Abstract][Full Text] [Related]
20. A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).
Yoshida S; Takahara T; Arita Y; Ito M; Hayakawa S; Oguchi T; Komai Y; Numao N; Yuasa T; Inoue M; Ushijima H; Kudo S; Shimano Y; Nakamura Y; Uchida Y; Uehara S; Tanaka H; Yaegashi H; Izumi K; Yokoyama M; Matsuoka Y; Yoshioka Y; Konishi K; Nakanishi K; Nagahara A; Hirakawa A; Koike R; Koga F; Nishimura K; Mizokami A; Yonese J; Kageyama Y; Yoshimura R; Fujii Y
BMC Urol; 2023 Mar; 23(1):33. PubMed ID: 36879257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]